The greater efficacy of sparsentan compared with an ARB in multiple aspects of renal pathophysiology underscores the importance of the interplay of ET-1 and AngII signaling in the pathogenesis and therapy of FSGS. Here, AGT is linked to focal segmental glomerulosclerosis.